Monday, August 11, 2003 1:40:01 PM
DNAP does not have any drugs yet. If they have anything worth stealing at this time it is the genomic IP.
If a pharma has the technical expertise to recognize the 'value' of DNAP's technology then they have the capability to duplicate it given the nature of the patent process.
The instructions for patent disclosure require that the application be written such that a person 'practiced in the art' could duplicate and use the discovery presented in the application.
With the purchase of a machine equivalent to the 'borrowed' Orchid device and a copy of the patent, anyone adept in the art can duplicate the discovery. Potentially, with enough money and duplicity, inconsequential changes could be made to get around the patent itself.
The fact that no one seems to be chomping at their heels might be more indicative of a lack of interest than a lack of capability.
frog
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM